nach oben

Erschienen in:

2010 | OriginalPaper | Buchkapitel

7. Ecopharmacostewardship – A Pharmaceutical Industry Perspective

verfasst von : David Taylor

Erschienen in: Green and Sustainable Pharmacy

Verlag: Springer Berlin Heidelberg

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

Until the late 1990s, the environmental impact of the pharmaceutical industry was universally considered to be very minor. Any environmental impact was considered to arise from manufacturing facilities and these were relatively small in size with well controlled emissions. It was appreciated that the pharmaceuticals themselves were biologically active, but in view of the small quantities being manufactured and the high cost of production, releases to the environment from manufacturing were expected to be very small.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Vorheriges Kapitel Reducing the Ecological Footprint of Pharmaceutical Usage: Linkages Between Healthcare Practices and the Environment

Nächstes Kapitel Protein and Peptide Therapeuticals: An Example of “Benign by Nature” Active Pharmaceutical Ingredients

Knowledge and need assessment of pharmaceutical products in environmental waters [http://www.knappe-eu.org].

Prions cause a number of diseases in a variety of animals and Creutzfeldt-Jakob disease (CJD) in humans.

However, unlike the situation with veterinary pharmaceuticals, a human pharmaceutical cannot be denied marketing authorisation because of adverse environmental effects. The environmental authorities may, of course, use the data to impose strict discharge limits into the environment.

Vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates and lipids are exempted because they are unlikely to result in significant risk to the environment. Similarly, vaccines and herbal medicinal products are also exempted due to the nature of their constituents.

Alder AC, Bruchet A, Carballa MC, Clara M, Joss A, Löffler CS, McArdell KM, Miksch K, Omil F, Tuhkanen T, Ternes T (2006) Consumption & occurrence. In: Ternes T and Joss A (eds.) Human Pharmaceuticals, Hormones and Fragrances – The Challenge of Micropollutants in Urban Water Management. IWA Publishing, London, pp. 15–54

Anastas PT, Warner JC (1998) Green Chemistry: Theory and Practice. Oxford University Press, Oxford

Anon (2005) Environmentally Classified Pharmaceuticals. Stockholm County Council

Anon (2007a) Environmental classification of pharmaceuticals in http://www.fass.se: guidance for pharmaceutical companies, January 2007. Swedish Association of the Pharmaceutical Industry Stockholm

Anon (2007b) Product Stewardship Institute Web: http://www.productstewardship.us/displaycommon.cfm?an=1&subarticlenbr=55

AstraZeneca (2008) Responsibility – Climate Change. Web: http://www.astrazeneca.com

Boxall A, Brooks B, Backhaus T, Gouy D, Hickman S, Kidd K, Metcalfe C, Monteiro S, Netherton M, Parrot J, Smith E, Straub JO, Weeks J (2008) Ecotoxicology of pharmaceuticals: Making sense of the published literature. EU Framework 6 Project KNAPPE Deliverable number: D4.1. Report of the WP4 Workshop; 28–31 January, 2008, Harrogate, UK

BristolMyers Squibb (2007) Land Use & Biodiversity. Web: http://www.bms.com/ehs/perfor/data/landus.html

Clarke J, Summerton L (2010) Challenges and opportunities for incorporating green chemistry into drug design to minimise environmental impact. (In press)

Crow JM (2008) Pharma goes green to cut costs. Chemistry World, July 2008

Cunningham VL, Buzby M, Hutchinson TH, Mastrocco F, Parke N, Roden N (2006) Effects of human pharmaceuticals on aquatic life: Next steps. Environ Sci Technol 40, 3457–3462

Curzons AD, Constable DC, Cunningham VL (1999) Solvent selection guide: A guide to the integration of environmental, health and safety criteria into the selection of solvents. Clean Products Process 1, 82–90

Daughton CG (2003) Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health Part I: Rationale for and avenues towards a green pharmacy. Environ Health Perspect, May 2003

Dunn P, Wells A, Williams MT (2010) Green Chemistry in the Pharmaceutical Industry. Wiley, Germany

EC (2000) Directive 2000/60/ec of the European Parliament and of the Council of 23 October 2000 establishing a framework for Community action in the field of water policy. Official Journal L327 22/12/2000: 1–72

EC (2004) Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal L136 30/04/2004: 34–57

EMEA (2007) Guideline on the environmental risk assessment of medicinal products for human use. European medicines Evaluation Agency Guidance Note EMEA/CHMP/SWP/4447/00. Web: http://www.emea.europa.eu/pdfs/human/swp/444700en.pdf

EPA (2008) Presidential Green Chemistry Challenge 2008. Web: http://www.epa.gov/gcc/pubs/pgcc/presgcc.html

GlaxoSmithKline (2007) Answering the questions that matter. Corporate Responsibility Report 2007. Web: http://http://www.gsk.com/reportsandpublications.htm

Halling-Sørensen B, Nielsen SN, Lanzky PF, Ingerslev F, Holten-Lützhøft HC, Jørgensen SE (1998) Occurrence, Fate and Effects of Pharmaceutical Substances in the Environment: A Review. Chemosphere 36, 357–393

IFPMA (2008) Web: http://http://www.ifpma.org/index.php?id=600

Kümmerer K (ed.) (2004) Pharmaceuticals in the Environment. 2nd edition, Springer-Verlag, New York

Kümmerer K (2007) Sustainable from the very beginning: rational design of molecules by lifecycle engineering as an important approach for green pharmacy and green chemistry. Green Chem 9, 899–907CrossRef

Kümmerer K, Al-Ahmad A, Bertram B, Wießler M (2000) Biodegradability of antineoplastic compounds in screening tests: Influence of glucosidation and of stereochemistry. Chemosphere 40, 767–773CrossRef

Larsson DGL, de Pedro C, Paxeus N (2007) Effluent from drug manufactures contains extremely high levels of pharmaceuticals. J Hazard Mater 148(3), 751–755CrossRef

Mattson B, Näsman I, Ström J (2007) Sweden’s voluntary drug environmental classification system. RAJ Pharma, 153–158

ONDCP (2007) Proper Disposal of Prescription Drugs. US Office of National Drug Control Policy, Washington, DC. Web: http://www.whitehousedrugpolicy.gov/

Owen SF, Giltrow E, Huggett DB, Hutchinson TH, Saye J, Winter MJ, Sumpter JP (2007) Review: Comparative physiology, pharmacology and toxicology of ß-blockers: Mammals versus fish. Aquat Toxicol 82, 145–162CrossRef

Pfizer (2007) Water Use & Conservation. Web: http://www.pfizer.com/responsibility/ehs/conserving_water_performance.jsp

PwC (2007) Pharma 2020: The Vision. Which Path Will You Take? PriceWaterHouse Coopers, London

Ramessar K, Capell T, Christou P (2008) Molecular pharming in cereal crops. Phytochem Rev 7, 579–592CrossRef

Richardson ML, Bowron JM (1985) The fate of pharmaceutical chemicals in the aquatic environment. J Pharm Pharmacol 37, 1–12CrossRef

Ruhoy IS, Daughton CG (2008) Beyond the medicine cabinet: An analysis of why & where medications accumulate. Environ Int 34, 1157–1169CrossRef

Sheldon RA (1994) Consider the Environmental Quotient. Chemtech 24, 38–47

Stan HJ, Heberer T, Linkerhägner M (1994) Occurrence of clofibric acid in the aquatic system – does the medical application cause contamination of surface, ground and drinking water? Vom Wasser 83, 57–68

Taylor D, Poulmaire M (2008) An initial survey of unused & expired medicine take-back schemes in the European Union. Poster Presentation Pharmaceutical Products in the Environment: Towards Lowering Occurrence and Impact KNAPPE International Conference. Nimes (France)

Thomas KV, Dye C, Schlabach M, Langford KH (2007) Source to sink tracking of selected human pharmaceuticals from two Oslo city hospitals and a wastewater treatment works. J Environ Monit 9, 1410–1418CrossRef

United Nations (2002) Convention on the Conservation of Biological Diversity. Web: http://www.biodiv.org/convention/default.shtml

Titel: Ecopharmacostewardship – A Pharmaceutical Industry Perspective
verfasst von: David Taylor
Verlag: Springer Berlin Heidelberg
Buch: Green and Sustainable Pharmacy
Print ISBN: 978-3-642-05198-2

Electronic ISBN: 978-3-642-05199-9

Copyright-Jahr: 2010
DOI: https://doi.org/10.1007/978-3-642-05199-9_7